

Electronic Acknowledgement Receipt

EFS ID:	5096376
Application Number:	10612179
International Application Number:	
Confirmation Number:	5239
Title of Invention:	Method and medicament for inhibiting the expression of a given gene
First Named Inventor/Applicant Name:	Roland Kreutzer
Customer Number:	76634
Filer:	Allyson Russell Hatton
Filer Authorized By:	
Attorney Docket Number:	A2038-706120
Receipt Date:	03-APR-2009
Filing Date:	02-JUL-2003
Time Stamp:	18:58:07
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	4318
Deposit Account	502762
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	A2038_706120_IDS_itr.pdf	22012 0e176a2f1d425c0342e777eebd180f558b7e615	no	1
Warnings:					
Information:					
2	NPL Documents	Burke_Appearance.pdf	558597 711e2b55e4095b112ef76c1d9e92abb081e129	no	6
Warnings:					
Information:					
3	NPL Documents	Barlow_Interferon.pdf	621344 e3e0f6a621d11e1c3e3e1e95ae01713c51229d65	no	7
Warnings:					
Information:					
4	NPL Documents	Decision_EP1144623_translation_032909.pdf	2370160 6ec2775c8baae13bba8c0d78141c40d9ab94d8	no	50
Warnings:					
Information:					
5	NPL Documents	Decision_revoking_patent_and_grounds_033109.pdf	1293302 c03108f940a82c5d4f006596d126d504bc865	no	33
Warnings:					
Information:					
6	NPL Documents	Harada_Absence.pdf	807102 c1896c5d80c91c0e8f1c04c7c611b7b9e9f66	no	10
Warnings:					
Information:					
7	NPL Documents	Nakamura_RNase.pdf	1621543 973f488bbcc29672d1d7261a1919a77b1c55f1f	no	5
Warnings:					
Information:					
8	NPL Documents	Not_Opp_Oppl_062008.pdf	806003 075f8ea377ebc135c1966bdc5eeba84dc2c86e6	no	24
Warnings:					

Information:					
9	NPL Documents	Not_Opp_Pfizer_061908.pdf	573087 dd412f0081c2e2f6e0163b6f501300a274de	no	15
Warnings:					
Information:					
10	NPL Documents	Not_Opp_Sanofi_061608.pdf	1102132 5761808186cf6a697a2003d4a895e2b4f939d7f	no	22
Warnings:					
Information:					
11	NPL Documents	Not_Opp_Silence_062008.pdf	780815 6ec5f816e60af94f6ca447cd3e13be5ce597875	no	19
Warnings:					
Information:					
12	NPL Documents	Not_Opp_Sirna_062008.pdf	1769300 21e9286a105e6d85e779a254595397081428128	no	38
Warnings:					
Information:					
13	NPL Documents	Submission_Pfizer_DE10080167.pdf	183695 a9c3e6d238f5b353088a02fbae9201f67024b7c	no	4
Warnings:					
Information:					
14	NPL Documents	Submission_Sirna_DE10080167_030409.pdf	1868728 cac07d0708e0feda74e997bde7921de9c1093d	no	35
Warnings:					
Information:					
15	NPL Documents	Submission_Oppl_DE10080167_030409.pdf	367768 975779530923437c6e5c6f05e68371de7bc34b2b	no	7
Warnings:					
Information:					
16	NPL Documents	Patentees_Obser_DE10066235_Alnylam_020409.pdf	3097966 e8b2a1c77de400c168809c315c9c6a768d9d909	no	58
Warnings:					
Information:					
17	NPL Documents	Patentees_observ_DE10080167_030409.pdf	367768 975779530923437c6e5c6f05e68371de7bc34b2b	no	7
Warnings:					

Information:					
18	NPL Documents	Submission_Alnylam_trsl_DE1 0080167_030409.pdf	603222	no	21
			b0d6778f95d7dd81e04b4ed701b6099c6d231dc3		
Warnings:					
Information:					
19	Information Disclosure Statement (IDS) Filed (SB/08)	706121_sb08_040309.pdf	42167	no	5
			bdb8ebdc12d4c270c7ee4cb29f6b75ec073d20bc2		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
20	Fee Worksheet (PTO-06)	fee-info.pdf	29952	no	2
			a18f54c42910ac30f6425654f53c0d5c0edc		
Warnings:					
Information:					
Total Files Size (in bytes):			18886663		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					